What risks and matters should I pay attention to during treatment with nemolizumab?

Nemolizumab (Nemolizumab), as an innovative biological agent targeting interleukin‑31 receptor α (IL‑31Rα), is mainly used to treat chronic nodular pruritus and moderate to severe atopic dermatitis. Its unique mechanism of action allows the drug to show significant efficacy in relieving itching and improving skin symptoms, making it a treatment option that has attracted much attention in clinical practice. However, while any drug is effective, there are also certain risks and precautions for use. In order to ensure patient medication safety and therapeutic efficacy, it is particularly important to understand and pay attention to potential risks and related matters during nemolizumab treatment.

1. Risk of allergies and hypersensitivity reactions

Although nemolizumab is a highly specific monoclonal antibody, it is still possible to trigger allergic reactions. In clinical reports, some patients have mild allergic symptoms such as rash, itching, and urticaria, and a very small number of patients may suffer from severe anaphylactic shock (such as difficulty breathing, facial swelling, etc.). Therefore, the first medication should be administered in a medical institution, and medical staff need to observe whether the patient develops allergic symptoms. If any abnormality is found, the medication should be stopped immediately and corresponding first aid measures should be taken. Patients should closely monitor their physical reactions during treatment and inform their doctors promptly if they experience any discomfort.

2. Infection risk and immune monitoring

As an immunomodulator, nemolizumab may have a certain impact on the patient's immune function, thereby increasing the risk of infection. Clinical trial data show that patients treated with the drug may develop symptoms of minor infections such as upper respiratory tract infection and nasopharyngitis. During use, patients should maintain good personal hygiene and avoid contact with infectious sources. Doctors should regularly monitor white blood cell counts and other immune indicators based on the patient's specific conditions, especially patients with low immune function or a history of chronic infection, who need to be extra cautious. When signs of infection such as persistent fever, cough, difficulty breathing, etc. occur, prompt evaluation and treatment should be carried out.

3. Injection site reactions and skin care

Nemolizumab is administered by subcutaneous injection, and injection site reactions are common side effects, including local redness, pain, itching, or induration. Although most injection site reactions are mild and transient, they may also affect the patient's medication experience. In order to reduce injection site reactions, patients should strictly follow the doctor's instructions for injections, choose appropriate injection sites and avoid repeated injections into the same area. After the injection, cold compress can be used to relieve discomfort. At the same time, pay attention to the injection area for signs of infection, such as increased redness and swelling, exudation, etc. If any abnormalities occur, seek medical attention promptly.

4. Pay attention to medication for special groups of people

Special attention should be paid to safety when using nemolizumab in elderly patients, patients with liver and kidney dysfunction, and those with multiple chronic diseases. Due to reduced physiological functions in the elderly, drug metabolism and clearance abilities may decrease after taking medication, increasing the risk of adverse reactions. Patients with impaired liver and kidney function may cause drug accumulation and require adjustment of dosage or extension of dosing intervals. In addition, there is currently insufficient safety data for pregnant and lactating women and should be avoided unless used with caution after a doctor has clearly weighed the benefits and risks.

5. Risk management of combined medication

Nemolizumab may interact with other immunomodulatory drugs, anti-infective drugs, or hormonal drugs, affecting its efficacy or increasing the risk of side effects. During treatment, you should inform your doctor in detail about all medications you are taking, including prescription drugs, over-the-counter drugs, and health supplements. In particular, patients taking other immunosuppressants at the same time should be closely monitored for infection risk and immune status. The doctor will adjust the treatment plan based on the patient's overall condition to avoid adverse drug interactions.

6. Mental health and lifestyle adjustment

People with chronic itching and skin diseases often suffer from psychological stress, anxiety and sleep disorders. During nemolizumab treatment, patients should pay attention to their mental health and seek psychological support or professional consultation when necessary. A reasonable lifestyle is equally important to the treatment effect, such as keeping the skin clean, avoiding irritating substances, eating a reasonable diet and exercising moderately, which can help enhance immunity and promote skin repair.

7. Regular follow-up visits and efficacy evaluation

During the period of treatment with nemolizumab, patients should visit their doctors regularly to evaluate the efficacy and safety. The doctor will adjust the treatment dose or dosage regimen based on symptom improvement and side effects. Through scientific efficacy evaluation, we can ensure that drugs maximize their effectiveness while reducing risks.

As an innovative drug for the treatment of chronic pruritus and atopic dermatitis, nemolizumab has demonstrated good efficacy and high safety. However, patients need to pay high attention to potential risks during medication and actively cooperate with doctors for monitoring and management. Reasonable medication guidance, adequate patient education and lifestyle adjustments can effectively improve treatment experience and efficacy, and achieve long-term safe and effective disease control.

Reference materials:https://www.drugs.com/